Intravenous vinflunine is indicated as monotherapy for the second-line treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelium after failure of a prior platinum-containing regimen. In this patient population, vinflunine added to best supportive care (BSC), provided a survival advantage over the use of BSC alone and, given the nature of the disease, had an acceptable tolerability profile.
展开▼
